Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 1995 Aug;87(8):554–559.

Ki-67 reactivity in breast carcinoma analyzed by a computer-assisted image system: preliminary results.

R Mir 1, H Johnson Jr 1, R Mathur 1, L Wise 1, L B Kahn 1
PMCID: PMC2607879  PMID: 7674345

Abstract

The proliferative index of 63 breast carcinomas was measured on Ki-67 immunostained frozen tissue sections with a computer-assisted image analysis system. The mean proliferative index in estrogen-positive breast carcinomas was lower than in estrogen-negative carcinomas. An inverse relationship between proliferative index and short-term disease-free survival was noted.

Full text

PDF
554

Images in this article

557Figure 1
on p.557
557Figure 2
on p.557

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson M. R., Hamlin I., Staunton M. D. The relative significance of prognostic factors in breast carcinoma. Br J Cancer. 1971 Dec;25(4):646–656. doi: 10.1038/bjc.1971.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allegra J. C., Lippman M. E., Simon R., Thompson E. B., Barlock A., Green L., Huff K. K., Do H. M., Aitken S. C., Warren R. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep. 1979 Aug;63(8):1271–1277. [PubMed] [Google Scholar]
  3. BLOOM H. J., RICHARDSON W. W., HARRIES E. J. Natural history of untreated breast cancer (1805-1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br Med J. 1962 Jul 28;2(5299):213–221. doi: 10.1136/bmj.2.5299.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barnard N. J., Hall P. A., Lemoine N. R., Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol. 1987 Aug;152(4):287–295. doi: 10.1002/path.1711520407. [DOI] [PubMed] [Google Scholar]
  5. Charpin C., Andrac L., Vacheret H., Habib M. C., Devictor B., Lavaut M. N., Toga M. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res. 1988 Aug 1;48(15):4368–4374. [PubMed] [Google Scholar]
  6. Charpin C., Andrac L., Vacheret H., Habib M. C., Devictor B., Lavaut M. N., Toga M. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res. 1988 Aug 1;48(15):4368–4374. [PubMed] [Google Scholar]
  7. Clark G. M., Dressler L. G., Owens M. A., Pounds G., Oldaker T., McGuire W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989 Mar 9;320(10):627–633. doi: 10.1056/NEJM198903093201003. [DOI] [PubMed] [Google Scholar]
  8. Clark G. M., McGuire W. L., Hubay C. A., Pearson O. H., Marshall J. S. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med. 1983 Dec 1;309(22):1343–1347. doi: 10.1056/nejm198312013092240. [DOI] [PubMed] [Google Scholar]
  9. Gentili C., Sanfilippo O., Silvestrini R. Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer. 1981 Aug 15;48(4):974–979. doi: 10.1002/1097-0142(19810815)48:4<974::aid-cncr2820480420>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  10. Gerdes J., Pickartz H., Brotherton J., Hammerstein J., Weitzel H., Stein H. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol. 1987 Dec;129(3):486–492. [PMC free article] [PubMed] [Google Scholar]
  11. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15;31(1):13–20. doi: 10.1002/ijc.2910310104. [DOI] [PubMed] [Google Scholar]
  12. Hedley D. W., Friedlander M. L., Taylor I. W., Rugg C. A., Musgrove E. A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983 Nov;31(11):1333–1335. doi: 10.1177/31.11.6619538. [DOI] [PubMed] [Google Scholar]
  13. Jensen E. V., Block G. E., Smith S., Kyser K., DeSombre E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr. 1971 Dec;34:55–70. [PubMed] [Google Scholar]
  14. Krieger W., Pickartz H., Brotherton J., Adamczewska K. Histomorphologie des Mammakarzinoms und Steroidrezeptorgehalt. Pathologe. 1983 Nov;4(6):281–286. [PubMed] [Google Scholar]
  15. Lovett E. J., 3rd, Schnitzer B., Keren D. F., Flint A., Hudson J. L., McClatchey K. D. Application of flow cytometry to diagnostic pathology. Lab Invest. 1984 Feb;50(2):115–140. [PubMed] [Google Scholar]
  16. McDivitt R. W., Stone K. R., Meyer J. S. A method for dissociation of viable human breast cancer cells that produces flow cytometric kinetic information similar to that obtained by thymidine labeling. Cancer Res. 1984 Jun;44(6):2628–2633. [PubMed] [Google Scholar]
  17. McGurrin J. F., Doria M. I., Jr, Dawson P. J., Karrison T., Stein H. O., Franklin W. A. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer. 1987 May 15;59(10):1744–1750. doi: 10.1002/1097-0142(19870515)59:10<1744::aid-cncr2820591012>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  18. Meyer J. S., Connor R. E. In vitro labeling of solid tissues with tritiated thymidine for autoradiographic detection of S-phase nuclei. Stain Technol. 1977 Jul;52(4):185–195. doi: 10.3109/10520297709116774. [DOI] [PubMed] [Google Scholar]
  19. Meyer J. S., Friedman E., McCrate M. M., Bauer W. C. Prediction of early course of breast carcinoma by thymidine labeling. Cancer. 1983 May 15;51(10):1879–1886. doi: 10.1002/1097-0142(19830515)51:10<1879::aid-cncr2820511021>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  20. Meyer J. S., Hixon B. Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res. 1979 Oct;39(10):4042–4047. [PubMed] [Google Scholar]
  21. Meyer J. S., Lee J. Y. Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res. 1980 Jun;40(6):1890–1896. [PubMed] [Google Scholar]
  22. Nemoto T., Vana J., Bedwani R. N., Baker H. W., McGregor F. H., Murphy G. P. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980 Jun 15;45(12):2917–2924. doi: 10.1002/1097-0142(19800615)45:12<2917::aid-cncr2820451203>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  23. Olszewski W., Darzynkiewicz Z., Rosen P. P., Schwartz M. K., Melamed M. R. Flow cytometry of breast carcinoma: II. Relation of tumor cell cycle distribution to histology and estrogen receptor. Cancer. 1981 Aug 15;48(4):985–988. doi: 10.1002/1097-0142(19810815)48:4<985::aid-cncr2820480422>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  24. Pence J. C., Kizilbash A. M., Kerns B. J., Marks J. R., Iglehart J. D. Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. J Surg Oncol. 1991 Sep;48(1):11–20. doi: 10.1002/jso.2930480104. [DOI] [PubMed] [Google Scholar]
  25. Rose C., Thorpe S. M., Mouridsen H. T., Andersen J. A., Brincker H., Andersen K. W. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer. Breast Cancer Res Treat. 1983;3(1):77–84. doi: 10.1007/BF01806237. [DOI] [PubMed] [Google Scholar]
  26. Schiodt T. Breast carcinoma. A histological and prognostic study of 650 followed-up cases. Dan Med Bull. 1967 Sep;14(9):239–243. [PubMed] [Google Scholar]
  27. Sigurdsson H., Baldetorp B., Borg A., Dalberg M., Fernö M., Killander D., Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990 Apr 12;322(15):1045–1053. doi: 10.1056/NEJM199004123221505. [DOI] [PubMed] [Google Scholar]
  28. Tubiana M., Pejovic M. H., Chavaudra N., Contesso G., Malaise E. P. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer. 1984 Apr 15;33(4):441–445. doi: 10.1002/ijc.2910330404. [DOI] [PubMed] [Google Scholar]
  29. Tubiana M., Pejovic M. J., Renaud A., Contesso G., Chavaudra N., Gioanni J., Malaise E. P. Kinetic parameters and the course of the disease in breast cancer. Cancer. 1981 Mar 1;47(5):937–943. doi: 10.1002/1097-0142(19810301)47:5<937::aid-cncr2820470520>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES